重组人促卵泡激素在中国辅助生殖技术控制性卵巢刺激中的成本效益分析
Recombinant Human Follicle-Stimulating Hormone in Controlled Ovarian Hyperstimulation with Assisted Reproductive Technology in China: A Cost-Effectiveness Analysis.
作者信息
Li Hongchao, He Wei, Lin Hongbo, Du Angying, Zhang Xue, Yang Han, Qu Shuli
机构信息
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, People's Republic of China.
Fertility and Reproductive Medicine Centre, The Southwest Hospital of AMU, Chongqing, 400038, People's Republic of China.
出版信息
Risk Manag Healthc Policy. 2024 May 27;17:1387-1394. doi: 10.2147/RMHP.S456277. eCollection 2024.
BACKGROUND
To compare the cost-effectiveness of originator (reference) recombinant human follicle stimulating hormone alfa (rhFSH-α) (follitropin alfa, GONAL-f) and its biosimilar (rhFSH, JinSaiHeng) in assisted reproductive technology (ART) from a Chinese patient perspective.
METHODS
A decision tree model was developed to simulate the treatment pathway of infertile women undergoing ART using GONAL-f or JinSaiHeng. Published clinical and cost data were used to evaluate the cost-effectiveness of the rhFSH-α. The cumulative live birth rate (CLBR), direct medical costs and costs per cumulative live birth were estimated via an analytic decision-tree model.
RESULTS
CLBR of GONAL-f was higher than JinSaiHeng preparation (88.3% vs 84.4%), while the cost per cumulative live birth was lower (51,475 vs 52,095 CNY).
CONCLUSION
The originator rhFSH-α was associated with higher CLBR and lower cost per cumulative live birth, with incremental cost per additional live birth of 38,096 CNY (Chinese Yuan).
背景
从中国患者角度比较原研（参比）重组人促卵泡激素α（rhFSH-α）（果纳芬，GONAL-f）及其生物类似药（rhFSH，金赛恒）在辅助生殖技术（ART）中的成本效益。
方法
建立决策树模型以模拟使用GONAL-f或金赛恒接受ART治疗的不孕女性的治疗路径。已发表的临床和成本数据用于评估rhFSH-α的成本效益。通过分析决策树模型估计累积活产率（CLBR）、直接医疗成本和每累积活产的成本。
结果
GONAL-f的CLBR高于金赛恒制剂（88.3%对84.4%），而每累积活产的成本较低（51,475元对52,095元）。
结论
原研rhFSH-α与更高的CLBR和更低的每累积活产成本相关，每增加一例活产的增量成本为38,096元（人民币）。
Zotero 插件